Cargando…

Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study

The purpose was to analyze statin effectiveness in a general population with differing levels of coronary heart disease (CHD) risk. Patients (35–74 years) without previous cardiovascular disease were included and stratified according to 10‐year CHD risk (<5%, 5–7.4%, 7.5–9.9%, and 10–19.9%). New...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia‐Gil, Maria, Comas‐Cufí, Marc, Blanch, Jordi, Martí, Ruth, Ponjoan, Anna, Alves‐Cabratosa, Lia, Petersen, Irene, Marrugat, Jaume, Elosua, Roberto, Grau, María, Ramos, Rafel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174924/
https://www.ncbi.nlm.nih.gov/pubmed/29194590
http://dx.doi.org/10.1002/cpt.954
_version_ 1783361388567068672
author Garcia‐Gil, Maria
Comas‐Cufí, Marc
Blanch, Jordi
Martí, Ruth
Ponjoan, Anna
Alves‐Cabratosa, Lia
Petersen, Irene
Marrugat, Jaume
Elosua, Roberto
Grau, María
Ramos, Rafel
author_facet Garcia‐Gil, Maria
Comas‐Cufí, Marc
Blanch, Jordi
Martí, Ruth
Ponjoan, Anna
Alves‐Cabratosa, Lia
Petersen, Irene
Marrugat, Jaume
Elosua, Roberto
Grau, María
Ramos, Rafel
author_sort Garcia‐Gil, Maria
collection PubMed
description The purpose was to analyze statin effectiveness in a general population with differing levels of coronary heart disease (CHD) risk. Patients (35–74 years) without previous cardiovascular disease were included and stratified according to 10‐year CHD risk (<5%, 5–7.4%, 7.5–9.9%, and 10–19.9%). New users were categorized according to their medical possession ratio (MPR). The main outcome was atherosclerotic cardiovascular disease (ASCVD) (myocardial infarction and ischemic stroke). In adherent patients (MPR 70%), statin treatment decreased ASCVD risk across the range of coronary risk (from 16–30%). The 5‐year number needed to treat (NNT) was 470 and 204 in the risk categories <5% and 5–7.4%, respectively, and 75 and 62 in the 7.5–9.9% category than in the 10–19.9% category, respectively. Statin therapy should remain a priority in patients at high 10‐year CHD risk (10–19.9%). Most patients with intermediate risk could benefit from statin treatment, but the treatment decision should focus on the net benefit, safety, and patient preference, given the higher NNT.
format Online
Article
Text
id pubmed-6174924
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61749242018-10-10 Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study Garcia‐Gil, Maria Comas‐Cufí, Marc Blanch, Jordi Martí, Ruth Ponjoan, Anna Alves‐Cabratosa, Lia Petersen, Irene Marrugat, Jaume Elosua, Roberto Grau, María Ramos, Rafel Clin Pharmacol Ther Research The purpose was to analyze statin effectiveness in a general population with differing levels of coronary heart disease (CHD) risk. Patients (35–74 years) without previous cardiovascular disease were included and stratified according to 10‐year CHD risk (<5%, 5–7.4%, 7.5–9.9%, and 10–19.9%). New users were categorized according to their medical possession ratio (MPR). The main outcome was atherosclerotic cardiovascular disease (ASCVD) (myocardial infarction and ischemic stroke). In adherent patients (MPR 70%), statin treatment decreased ASCVD risk across the range of coronary risk (from 16–30%). The 5‐year number needed to treat (NNT) was 470 and 204 in the risk categories <5% and 5–7.4%, respectively, and 75 and 62 in the 7.5–9.9% category than in the 10–19.9% category, respectively. Statin therapy should remain a priority in patients at high 10‐year CHD risk (10–19.9%). Most patients with intermediate risk could benefit from statin treatment, but the treatment decision should focus on the net benefit, safety, and patient preference, given the higher NNT. John Wiley and Sons Inc. 2018-02-02 2018-10 /pmc/articles/PMC6174924/ /pubmed/29194590 http://dx.doi.org/10.1002/cpt.954 Text en © 2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Garcia‐Gil, Maria
Comas‐Cufí, Marc
Blanch, Jordi
Martí, Ruth
Ponjoan, Anna
Alves‐Cabratosa, Lia
Petersen, Irene
Marrugat, Jaume
Elosua, Roberto
Grau, María
Ramos, Rafel
Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study
title Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study
title_full Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study
title_fullStr Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study
title_full_unstemmed Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study
title_short Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population‐Based Cohort Study
title_sort effectiveness of statins as primary prevention in people with different cardiovascular risk: a population‐based cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174924/
https://www.ncbi.nlm.nih.gov/pubmed/29194590
http://dx.doi.org/10.1002/cpt.954
work_keys_str_mv AT garciagilmaria effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy
AT comascufimarc effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy
AT blanchjordi effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy
AT martiruth effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy
AT ponjoananna effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy
AT alvescabratosalia effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy
AT petersenirene effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy
AT marrugatjaume effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy
AT elosuaroberto effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy
AT graumaria effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy
AT ramosrafel effectivenessofstatinsasprimarypreventioninpeoplewithdifferentcardiovascularriskapopulationbasedcohortstudy